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Abstract: Abdominal Aortic Aneurysms (AAAs) are associated with advanced age, male gender, cigarette smoking,
atherosclerosis, hypertension, and genetic predisposition. Basic research studies have led to a better understanding of
aneurysm disease over the past two decades. There has also been a growing appreciation that fundamental knowledge
regarding the process of aneurysmal degeneration is still somewhat limted. Opportunities in research include: 1) the
investigation of potential new mechanism-based pharmacologic interventions; 2) identify the genetic basis for an
inherited predisposition; 3) develop and refine noninvasive approaches for the early detection; 4) examine potential novel
surgical approaches and design new biomaterials; and 5) initiate and promote awareness programs for diagnosis and
treatment of aortic aneurysms. The optimal approach to addressing these issues will require integrative, multidisciplinary
research programs that involve basic scientists working in concert with vascular and cardiothoracic surgeons, as well as
other clinical specialists with expertise in vascular disease. ( J Vasc Surg 2007;45:192-8.)Aortic aneurysms are a common clinical condition with
life-threatening implications. Treatment for this condition
is currently limited to observation or surgical repair of the
diseased aorta, yet the high morbidity and mortality asso-
ciated with advanced aortic disease indicate that other
strategies are needed.1 It is expected that better knowledge
of the biological factors and mechanisms underlying the
development, growth, and rupture of aortic aneurysms will
promote the emergence of novel approaches by which to
better manage these diseases.2 Understanding the basic
pathobiology of aortic diseases has therefore become an
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192increasing priority in basic and translational vascular re-
search.
Current research on aortic disease encompasses inves-
tigations on the genetic and environmental factors associ-
ated with development of aortic aneurysms, mechanistic
studies on the fundamental pathophysiology of aortic de-
generation and aneurysm formation, elucidation of the role
of biomechanical stresses in the biology of the aneurysmal
aortic wall, and development of novel strategies for disease
prevention and treatment. Many of these studies have been
supported through recent initiatives from the National
Heart, Lung, and Blood Institute.2 This article presents a
brief summary of unresolved research problems to help
guide further research efforts in this area.
ETIOLOGY
Abdominal aortic aneurysms (AAAs) are known to be
associated with advanced age, male sex, cigarette smoking,
atherosclerosis, hypertension, and a genetic predisposition.3
Although these epidemiologic associations are widely rec-
ognized, the specific relationships between various risk
factors and the development of aneurysm disease are not
well understood. This uncertainty is exemplified by the
limited knowledge of the role played by atherosclerosis in
aneurysmal degeneration, where debate continues as to
whether atherosclerosis is a “bystander” condition or an
active participant in the development and progression of
disease.4,5
For example, the abdominal aorta is a region prone to
develop advanced atherosclerotic lesions, and the presence
of atherosclerosis is an almost ubiquitous finding in AAA
tissue. In addition to the physical presence of atherosclero-
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diseases seems to be promoted by some similar risk factors
that include smoking, hypercholesterolemia, and increased
systolic blood pressure. These observations support the
traditional view that atherosclerosis is an active component
in the process of aortic dilation; however, it is not clear
whether the presence of atherosclerosis equates to an active
role in aorta enlargement. Alternatively, it has also been
argued that atherosclerosis is formed as a consequence of
aneurysms. Some of the arguments against the active in-
volvement of atherosclerosis in AAA formation include the
following: (1) atherosclerotic lesions form in many loca-
tions in the vasculature, but most are not associated with
aneurysmal development; (2) atherosclerosis is a very com-
mon disease in industrialized nations, although a much
smaller segment of the population seems to develop AAA;
and (3) it is not clear that the pharmacologic agents that
influence atherosclerosis also influence the development of
AAA.
The link between AAA formation and atherosclerosis is
also not strong in animal models. Despite the numerous
studies that have induced atherosclerosis by a variety of
dietary and genetic means, only a small number have re-
ported the occurrence of AAAs.6 However, the low inci-
dence of AAAs in these studies may be due to many being
performed in a time frame that may be too brief for the
development of AAAs. Conversely, many of the animal
models of AAA do not require the presence of atheroscle-
rosis. This includes the models that are in current common
use, such as adventitial application of calcium chloride and
intraluminal delivery of elastase.7,8 A link to atherosclerosis
may be inferred by the observation that AAAs are formed
during infusion of angiotensin II in hyperlipidemic ani-
mals.9 However, angiotensin II infusion also leads to the
development of AAAs in normolipidemic mice, albeit at a
lesser incidence; aneurysm formation in the angiotensin II
model is not located at sites of atheromatous plaques, and
angiotensin-induced aneurysms seem to be the result of
focal dissections linked to transient hypertension.10 There-
fore, it is not clear whether hyperlipidemia augments the
effectiveness of angiotensin II rather than acting via an
effect on atherosclerosis. There are also several studies in
which the deletion of specific genes has led to a dichotomy
of effects on atherosclerosis and aneurysms, including de-
letion of MMP3 and TIMP1. These animal studies must
therefore be interpreted in the context of the current
uncertainty regarding the mechanisms underlying these
models and whether they recapitulate all of the features of
human aneurysm disease.11,12
Thus, the definition of the role of atherosclerosis in the
development of AAA is an important mechanistic link to
establish. Although it will be difficult to provide definitive
evidence for an association or dissociation of atherosclerosis
in AAA formation, these efforts will have important thera-
peutic implications for the treatment of AAAs. Moreover,
evidence of dissociation between atherosclerosis and AAAs
provide an indication that further mechanistic insight intoAAAs is needed if novel therapeutic strategies are to be
developed.
GENETIC FACTORS IN AORTIC ANEURYSMS
Genetic factors have been established to play a role in
the etiology of thoracic aortic aneurysms and dissection
(TAAD).13 Marfan syndrome (MFS) is a well-characterized
genetic syndrome that involves the cardiovascular, ocular,
and skeletal systems. The life-threatening complication of
MFS is progressive enlargement of the ascending thoracic
aorta leading to acute aortic dissection and aneurysm for-
mation. Prophylactic repair of the aorta before an aneurysm
reaches a sufficient size to threaten dissection leads to
substantial improvement in the life expectancy for this
population, thus emphasizing the need to identify individ-
uals at risk for this type of aortic disease.
Recent studies have begun to elucidate the genes that
predispose individuals to ascending aortic aneurysms and
dissections who do not have MFS. Familial aggregation
studies have demonstrated that up to 20% of patients
referred for surgical intervention of this condition have a
first-degree relative who also has aortic disease.13 Familial
TAAD is inherited in families as primarily an autosomal
dominant condition with decreased penetrance and vari-
able expression. A major locus for this condition, termed the
TAAD1 locus, has been mapped to 5q13-14, and minor loci
have been identified at 11q23-24 (termed the FAA1 locus)
and 3p24-25 (termed the TAAD2 locus).13,14 Further
genetic heterogeneity is evident because some families do
not have demonstrated evidence of linkage to any of the
known loci.13 Identification of TAAD families, along with
mapping and identifying the defective genes that cause this
condition, is important for understanding the disease process
and identifying individuals at risk for this life-threatening
condition. Future studies involving imaging or biomarkers
of the disease process could be potentially studied in these
families in which the genetic risk for developing the disease
can be determined before the onset of overt aortic disease.
Genetic studies of AAAs indicate that different genetic
risk factors are involved in the development of these two
forms of aortic disease. Approximately 15% of patients with
AAAs have a positive family history for AAA,15 and segre-
gation studies have favored a major autosomal gene as the
cause of familial aggregation of the disease.16,17 Two loci
for the condition have been mapped to locations distinct
from the loci identified for TAAD.13,14,18 The AAA loci are
on chromosome 19q13 (AAA1 locus) and 4q31 (AAA2
locus).18 There is evidence for genetic heterogeneity for the
condition, thus indicating that additional genetic loci need
to be identified.18
Another possible avenue for therapy is based on the
recent studies showing that fibrillin 1 and microfibrils reg-
ulate the transforming growth factor (TGF)- family of
growth factors (cytokines) that influence many aspects of
cellular performance, including differentiation, prolifera-
tion, protein production, and survival.19 Data in mice
demonstrate that a deficiency of fibrillin 1–containing mi-
crofibrils results in excessive TGF  activation and signaling
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tissues altered in the MFS.19 These data have led to a novel
paradigm suggesting that matrix sequestration of cytokines
is critical to their regulated activation and signaling and that
perturbation of this function can contribute to the patho-
genesis of diseases like MFS. Most recently, studies in
mouse models of MFS have demonstrated that inhibition
of TGF  signaling, through treatment with the angioten-
sin receptor antagonist losartan, can effectively suppress
aortic pathology.20 These remarkable findings have led to
the development of a National Heart, Lung, and Blood
Institute–supported prospective clinical trial (through the
Pediatric Heart Network) in which young patients with
MFS will be treated with either atenolol or losartan and
followed up longitudinally to observe and compare the
effects of drug treatment on aortic root dilatation.
HISTOPATHOLOGY OF AORTIC ANEURYSMS
The histopathologic features of human AAAs are char-
acterized by chronic transmural inflammation, destructive
remodeling of the elastic media, and depletion of medial
smooth muscle cells (SMCs).21,22 Defining the cellular and
molecular mechanisms underlying the distorted architec-
ture of aneurysms and dissections and elucidating the
pathophysiology of these processes have therefore re-
mained important areas of investigative focus. Translation
of knowledge regarding the pathophysiology of aneurysms
and dissections, as obtained from basic studies and animal
models, is also thought to be an extremely fruitful area for
clinical development.
It is now recognized that the destruction of elastin and
collagen is largely responsible for the decrease in aortic wall
tensile strength that accompanies aneurysmal dilatation.
Because these structural extracellular matrix proteins are
often resistant to degradation, it has become apparent that
proteinases capable of degrading elastin and collagen are
closely involved in the development and progression of
AAAs. Most recent work has focused on the role of various
matrix metalloproteinases (MMPs) as enzymatic mediators
of aneurysm disease, with special emphasis on MMP 2 and
MMP 9, which are both elastolytic and collagenolytic en-
zymes overexpressed in human and experimental AAAs.7,8,23
Additional work has focused on the relationship between
expression of these MMPs in aortic tissue and how they are
regulated by endogenous MMP inhibitors, tissue inhibitors
of metalloproteinases. Despite the progress made in this
area, it is also evident that other enzymes, such as cysteine
proteases and their inhibitors, may also play an undiscov-
ered role in aortic diseases. Indeed, early studies indicate
that circulating levels of cystatin C, the principal endoge-
nous inhibitor of cathepsins, are decreased in patients with
aortic dilatation and aneurysms.24 Further definition of the
proteinases involved in AAAs and their pathophysiological
functions is therefore needed to understand these potential
targets for therapy, because inhibition of elastin and colla-
gen degradation may be an extremely fruitful avenue for
novel approaches to clinical management.The cell types that seem to be responsible for the
production of different enzymes in AAAs include mononu-
clear phagocytes and activated tissue macrophages. Al-
though the molecular mechanisms regulating macrophage
expression of MMPs and other proteinases are under active
investigation, much remains to be learned regarding the
specific regulatory mechanisms that are most important
within diseased aortic tissue. There is also increasing evi-
dence that proteinase production by other cell types may
contribute to aneurysmal degeneration, such as vascular
SMCs, adventitial fibroblasts, neutrophils, and lympho-
cytes.
The cellular infiltrates observed in human and experi-
mental AAAs include B lymphocytes, T cells, and dendritic
cells, thus indicating that a chronic immune response is an
important aspect of aneurysmal degeneration.25 Evidence
also exists for local production of antibodies reactive with
endogenous aortic wall antigenic proteins, implying that
the immune response in AAAs includes an autoimmune
component.26 Although it remains unclear whether this
autoimmune response is a primary event or simply a conse-
quence of chronic inflammation and extensive tissue de-
struction, opportunities exist for defining how the humoral
immune response may modify progression of aortic disease.
Furthermore, there is little information available on the role
of the cellular immune response in AAAs. With the recog-
nition that T lymphocytes may play a substantial modifying
role to influence macrophage activity and proteinase pro-
duction, this has become an increasingly important area of
investigation. Recent studies suggest that the cellular im-
mune response in human AAAs includes immunoregula-
tory features consistent with a T-helper type 2 response, as
well as proinflammatory features compatible with T-helper
type 1 responses.25-27 This has raised the possibility that
fluctuations in the direction or type of cellular immune
response may underlie much of the heterogeneity observed
in aneurysm disease, both in patients and in experimental
animal models.
Although much attention has focused on the role of
connective tissue destruction in aortic aneurysms and dis-
sections, it is recognized that these conditions arise
through an imbalance between tissue destruction and en-
dogenous mechanisms of tissue repair. Insufficient knowl-
edge is available, however, on the factors modifying or
limiting connective tissue repair in the diseased aorta and
how these mechanisms might be favorably altered. Studies
on the depletion of medial SMCs and adventitial fibroblasts
are needed, along with efforts to understand how these
mesenchymal cell types regulate the structural elements of
the extracellular matrix. On the basis of recent work in
other model systems of vascular disease, another fruitful
area of investigation is the potential participation of bone
marrow–derived progenitor cells in repair and regeneration
of the diseased aorta. Understanding whether circulating
progenitor cells contribute to aortic repair, or whether the
capacity of this process might be intrinsically limited in
patients prone to develop AAAs, is an unexplored but
intriguing possibility.
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ogy and pathogenesis of the MFS and TAAD, none of the
current treatment modalities derive from this knowledge.
Indeed, with the exception of refinement in surgical and
imaging techniques, all of the treatment protocols that are
currently in place were conceived and initiated in the 1960s
and 1970s. A focus of future therapies could be directed at
preventing pathology in the aortic wall, which is character-
ized by fragmentation and degradation of elastic fibers and
loss of SMCs in the medial layer (termed medial degenera-
tion). Recent characterization of the mouse model for MFS
(mice after homozygous Fbn1 gene targeting) demonstrates
that elastogenesis proceeds despite a severe quantitative and
qualitative deficiency of fibrillin 1 microfibrils.28,29 Elastic
fibers show normal morphology at birth, and fragmenta-
tion and loss of elastic fibers is largely a secondary event in
these animal models of MFS, with a pathogenetic sequence
of loss of connecting filaments that normally serve as a
structural interface between elastic lamellae and neighbor-
ing SMCs leading to an altered phenotype of the SMCs,
which includes altered expression of multiple matrix ele-
ments, including increased expression of MMP 2, and
MMP 9. The net result is the initiation of local elastic fiber
destruction that correlates temporally and spatially with
elastic fiber calcification and infiltration of inflammatory
cells into the aortic media. Both increased expression of
MMP 2 andMMP 9 and the presence of inflammatory cells
have been demonstrated in the aortic media in aortas of
patients with MFS, and data suggest that the inflammatory
cells drive apoptosis of SMCs.30
It is apparent from recent studies in animal models of
AAAs that the development of aneurysms can be sup-
pressed by pharmacologic strategies to inhibit MMPs, such
as the use of tetracycline derivatives or genetic alterations that
eliminate the expression of either MMP 9 or MMP 2. 31,32
Clinical applications of this work have suggested thatMMP
inhibition might also be applicable to patients with small
asymptomatic AAAs, in an attempt to suppress the rate or
extent of aneurysm expansion.33 Further clinical develop-
ment and evaluation of these new therapeutic approaches
are therefore needed to fulfill the promise offered by these
early studies.
HETEROGENEITY OF AORTIC ANEURYSMS
Aortic aneurysms are a significant health problem, as
the 15thmost common cause of death in the United States.
Along the length of the aorta, significant heterogeneity
occurs in the distribution of aneurysmal disease. For exam-
ple, the prevalence of AAAs was found to be 21 in 100,000,
in contrast to 5.9 in 100,000 for thoracic aortic aneurysms,
per year in the Rochester, Minn, area. With thoracic aortic
aneurysms, 51% involved the ascending aorta, 11% the arch,
and 38% the descending thoracic aorta. Only 25% to 28% of
patients with thoracic aortic aneurysm will have a concom-
itant AAA, and in general, multisegmental disease is found
in only 12.6% of cases. Further understanding of this het-
erogeneity may provide new insights into the etiology andtreatment of aneurysms and other aortic diseases, such as
dissection, penetrating ulcer, and intramural hematoma.
Embryologically, the aorta has multiple cellular origins.
The ascending aorta originates from the truncus arteriosus,
the transverse aortic arch originates from the primitive arch
segments, and the descending thoracic and abdominal
aorta develop from paraxial rests of mesoderm lateral to the
notochord on either side that migrate and coalesce ven-
trally to form the dorsal aorta at approximately 24 days
development. Because the cellular origin of the thoracic
aorta is heterogeneous and also regionally distinct from the
tissue that eventually forms the abdominal aorta, it stands
to reason that regional heterogeneity may exist in the
biology of the aorta. Regionally, the medial layer of the
aortic wall is primarily composed of concentric lamellar
units consisting of a layer of elastic fibers with an associated
layer of SMCs.22 In humans, the number of medial elastic
lamellar units decreases from 55 to 60 in the ascending
aorta to approximately 26 at the iliac bifurcation. Studies
are required to further define the structural heterogeneity
of the aorta in health and disease.
At the cellular level, regional differences exist in vascu-
lar endothelial cell reactivity and the growth kinetics of
aortic vascular SMCs. Aortic vascular extracellular matrix
proteins have been found to be altered in aneurysmal
compared with normal aortic segments.34 Regional distri-
bution in collagen subtypes, microfibrillar proteins, desmin,
connexin 43, and connexin 45 has been identified.35 Re-
gional heterogeneity has also been demonstrated in impor-
tant enzyme systems such as the MMPs and their inhibitors
and in nitric oxide synthase.36 Alterations in adrenoceptor
subtypes exist by region, in addition to antioxidant defenses
and other cellular functions, such as calcium uptake. Addi-
tional differences may account for the altered vascular
response to agents such as cyclooxygenase inhibitors and
cyclosporine.37 Hypothesis-based investigations targeting
the differential cellular response within the various aortic
regions remain to be performed.
In animal models and in patients, pharmacologic agents
such as statins, doxycycline, and other MMP inhibitors;
cyclooxygenase inhibitors; and angiotensin receptor antag-
onists have all been shown to modulate the progression of
aortic aneurysms. Further studies directed toward clinical
utilization of pharmacologic agents in the prevention of
aortic aneurysms in both animals and, especially, humans
are justified. To this end, although many animal models of
AAA exist, relatively few exist for the thoracic aorta.38 More
cause-and-effect science as it relates to the thoracic aorta
would be possible with the introduction of more in vivo
models of thoracic aortic disease. Therefore, further devel-
opment of thoracic aortic disease models is required, in
addition to studies testing the regional heterogeneity of
aneurysm responses to various preventive treatments.
BIOMECHANICS AND IMAGING OF
AORTIC ANEURYSMS
It is clear that the risk of aneurysm rupture is directly
related to the hemodynamic stresses placed on the degen-
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resist tensile stress. Recent studies have helped to define the
manner in which hemodynamic stresses are altered in
AAAs, thus demonstrating that stress distribution is largely
a function of aneurysm size and geometry.39 New methods
to measure aortic wall stress are now being used to better
define the effect of wall tension and the presence of mural
thrombus on the underlying biology of AAAs.40,41 The
development of imaging techniques to map tensile wall
stress is therefore beginning to provide a new and exciting
tool to evaluate risk of rupture in aneurysms of different
sizes.
The current state of the art in imaging for aortic pathol-
ogy involves three primary areas: screening and surveil-
lance, preoperative assessment, and (for certain types of
aneurysm repair) postoperative evaluation.42-45 Several re-
cent large studies have demonstrated a lower incidence of
AAA rupture when screening is performed in selected pop-
ulations. Screening for AAA in these settings has been
shown to be cost-effective. However, effective general pop-
ulation screening programs in the United States are being
debated. Once they are implemented, the appropriate
thresholds for surgical intervention for AAAs and other
aortic pathology will continue to be refined. However, it
remains clear that some small AAAs will rupture, yet some
patients with larger AAAsmay never require surgery despite
their high risk, so better indices of rupture risk are clearly
needed. The appropriate thresholds for intervention in
thoracic aortic aneurysms (ascending and descending) and
chronic aortic dissections remain poorly defined compared
with those for AAAs.
Most strategies for intervention in aortic aneurysms
(with or without dissection) are based on maximum aneu-
rysm diameter.45 New imaging techniques with computed
tomography or magnetic resonance and three-dimensional
reconstruction have been suggested to evaluate aneurysm
wall tension or wall stress as a potentially better predictor
than aneurysm diameter.40,41 Such biomechanical methods
have produced some promising early results, but much
remains to be investigated in relation to biomechanical
analysis of the aorta, including thematerial properties of the
aorta in various locations, potential interactions with bio-
logic phenomena (eg, matrix metalloproteases), potential
effects of thrombus or calcification on material properties
or pressure transmission, effects of sex and body habitus,
effects of smoking on biomechanical factors, effects of flow
dynamics within the aorta on aneurysm formation and
rupture risk, potential use of dynamic or cine MR angiog-
raphy to evaluate wall properties and flow phenomena, the
relationship between biomechanical evaluation and pro-
gression of aneurysms, and noninvasive imaging for stress
analysis in high-risk populations (according to genetic or
other risk factors).
Although endovascular aneurysm repair has produced a
less invasive method for aneurysm repair, it has also pro-
duced a new area of aneurysm evaluation in which imaging
is crucial.46 The purpose of endovascular stent-graft repair
of an aneurysm is to diminish or eliminate the risk ofrupture by diminishing or eliminating the pressure within
the aneurysm sac. The predominant method of determin-
ing effective aneurysm exclusion is to measure maximum
diameter and to use a proxy for exclusion—namely, com-
plete thrombosis of the sac. There is much potential for
newer methods of evaluation, however. Multiple investiga-
tions in vascular and nonvascular tissues have demonstrated
that the three-dimensional volume detects size change
more effectively than maximum diameter. Magnetic reso-
nance scan techniques, such as dynamic or cine magnetic
resonance, have the capability of displaying aneurysm wall
motion in real time. These and other magnetic resonance
angiography techniques may be more sensitive for detect-
ing pressure and flow within the aneurysm sac after endo-
vascular repair and for evaluating flow within dissections.
Intrasac pressure sensors have demonstrated the potential
to directly monitor aneurysm pressure within the patient,
but the nature of pressure distribution within the thrombus
and how to address changes over time remain to be deter-
mined. Many of these techniques are also applicable to
preoperative evaluation of aortic pathology.
Finally, it is clear that the availability of large patient
databases has been a primary reason for recent progress in
determining rupture risks and size thresholds for interven-
tion in AAAs. Comparable databases of patients with aortic
pathology have just been initiated by the National Heart,
Lung, and Blood Institute with the hope of collecting
biological material and clinical data from patients with
aneurysms of varying sizes or patients at high risk for
developing aneurysms for whom information could be used
to refine predictions of rupture risk, investigate noninvasive
imaging techniques (such as wall stress analysis), investigate
genetic mechanisms, or develop algorithms for determin-
ing which elderly patients are highly unlikely to experience
aneurysm-related death. Also to be included are databases
of patients with other types of aortic pathology (ascending
and descending thoracic aneurysms, aortic dissections, and
penetrating ulcers), because these conditions are less com-
mon and difficult to study at any individual center. Data-
bases also provide a mechanism for collaborative investiga-
tion among those studying every aspect of aortic pathology,
including genetic markers, serum markers of biological
activity, medications, new imaging techniques, prediction
algorithms, indications for open or endovascular repair,
quality of life, and other issues.
OPPORTUNITIES FOR FUTURE RESEARCH
It is clear that a number of key areas seem to offer
substantial research opportunities for advancing knowledge
regarding aortic aneurysms and dissections. The optimal
approach to addressing these issues will require integrative,
multidisciplinary research programs that involve basic sci-
entists working in concert with vascular and cardiothoracic
surgeons and other clinical specialists with expertise in
vascular disease. The areas of greatest research opportuni-
ties would include the following broad topics.
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opment of aortic aneurysms and dissections, with an
emphasis on elucidating the biological mechanisms by
which specific risk factors might act to promote aortic
disease, such as atherosclerosis and hypertension. Appro-
priate studies in this area might be aimed at population-
based evaluation of risk and prevalence of aortic dis-
eases, as well as hypothesis-driven investigations of the
roles played by specific risk factors in both patients and
animal models of disease.
2. Elucidation of the genetic loci and molecular mecha-
nisms underlying familial aggregation of aneurysms,
including further analysis of loci already discovered to be
linked with aortic disease and new studies to identify
additional loci. Studies are also needed to determine the
genetic, molecular, and cellular mechanisms underlying
the development of aortic disease, such as those occur-
ring in MFS and other fibrillinopathies, as well as other
forms of inherited aneurysms and dissections.
3. Better definition of the cellular and molecular patho-
physiology of aneurysms, with emphasis on the mecha-
nisms underlying progressive destruction of aortic wall
connective tissue proteins, the role played by specific
proteinases in this process, and the endogenous mech-
anisms of connective tissue repair that might limit aortic
degeneration. The specific nature of cellular immune
responses in complex aortic diseases needs to be defined,
along with approaches aimed at modifying aortic wall
inflammation that might be applicable to clinical stud-
ies. Much better understanding of the role of medial
SMCs in aortic diseases is needed, including the mech-
anisms of SMC involvement in disease initiation and
progression and the mechanisms and implications of
SMC depletion. A potential role for bone marrow–
derived pluripotent cells in repair and regeneration of
damaged aortic tissue is an exciting area that needs to be
examined, along with studies exploring possible uses of
cell-based therapies for complex aortic diseases.
Much better understanding of the heterogeneity of
aortic diseases will help fill a crucial gap in knowledge of the
distribution of aneurysms and the predilection of these
diseases for different anatomic segments. Studies are
needed that include assessment of the heterogeneity of
aortic physiology and structural pathophysiology, animal
models of various types of aortic disease in different seg-
ments of the aorta, and clinically based investigations on
the distribution of aortic wall pathology.
Substantial opportunities exist for the translation of
research findings from studies using animal models to the
clinical management of patients with aortic disease; this is
exemplified by the use of losartan in patients with MFS and
by the use of MMP inhibitors to suppress aneurysm expan-
sion in patients with small AAAs. Studies are especially
needed to determine the potential for pharmacologic treat-
ments to promote the regression (contraction) of estab-
lished aneurysms. Application of novel treatment strategies
to other clinical problems related to aneurysms and dissec-tions is also needed, such as management of thoracic aortic
aneurysms, chronic aortic dissections, penetrating aortic
ulcers, and intramural hematomas.
Refinement of imaging techniques and strategies by
which to assess complex aortic disease is needed, according
to recent advances using computed tomography, MR im-
aging, and in vivo stress analysis. There seems to be great
potential to improve the stratification of clinical risk by
using new imaging modalities, particularly stress analysis,
and to examine the optimal utilization of these modalities
in patients subject to long-term follow-up either before or
after surgical treatment. Studies evaluating the relationship
between alterations in aortic wall stress and the underlying
pathophysiology of the aortic wall will be an important
adjunct to the use of these new imaging modalities. A final
area of immense interest is the use of emerging techniques
for functional imaging, such as applications of nanotech-
nology for molecular imaging, to potentially characterize
inflammatory and/or proteolytic activity within aortic tis-
sue. This approach also has the potential to provide local-
ized delivery of pharmaceutical agents to target the patho-
biological processes involved in aneurysmal degeneration.
The contributions provided by Alan Daugherty, PhD,
DSc, Mark Fillinger, MD, and Dianna Milewicz, MD,
PhD, are greatly appreciated.
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